Translational study demonstrates that gut microbiota-derived hyodeoxycholic acid inhibits acute myeloid leukemia progression, highlighting a microbiome-targeted therapeutic target.
Key Points
To investigate the role of gut microbiota composition and bile acid metabolism in acute myeloid leukemia progression and treatment response.
Analyzed gut microbiota and metabolomic profiles in 29 patients with acute myeloid leukemia across treatment stages using 16S rDNA sequencing and LC-QTOF-MS.
Conducted functional in vitro and in vivo studies evaluating Enterococcus faecalis fecal microbiota transplantation and hyodeoxycholic acid treatment in leukemic mouse models.
Higher baseline Enterococcus abundance and serum hyodeoxycholic acid levels correlated with greater gut microbiota alpha diversity and complete clinical remission.
Enterococcus faecalis fecal microbiota transplantation elevated hyodeoxycholic acid levels and reduced leukemic burden in mice, while hyodeoxycholic acid delayed progression, prolonged survival, and promoted leukemic apoptosis via NF-κB inhibition and mitochondrial dysfunction.